This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Glenmark Pharmaceuticals Limited
Drug Names(s): GRC 6211
Description: GRC 6211 is an antagonist of the transient receptor potential vanilloid sub-family 1 (TRPV1) ligand-gated cation channel (that is a channel for positive ions that is opened/closed in response to binding of a chemical messenger). TRPV1 is a target for capsaicin, and is expressed in human pain pathways and in sensory neurons that mediate nociceptive signaling.
Deal Structure: In October 2007, Eli Lilly acquired the rights to Glenmark's portfolio of transient receptor potential vanilloid sub-family 1 (TRPV1) antagonist molecules. Under the terms of the agreement, Glenmark will receive an upfront fee of $45 million and could receive up to an additional $215 million in potential development and sales milestones for the initial indication, as well as royalties on sales if GRC 6211 is successfully commercialized. If other indications are successfully developed, Glenmark would be entitled to additional milestones up to $90 million. Lilly will have marketing rights for North America, Europe and Japan, while Glenmark will retain the marketing rights in all other countries. Further Glenmark will have the right to co- promote GRC 6211 in the United States. Other terms of the deal were not disclosed.
In July 2009, Glenmark stated that the company recently received the rights back for GRC 6211 from Eli Lilly.
GRC 6211 News
Additional information available to subscribers only: